Advancing Metabolite Biomarkers in Neurodegenerative Disease: Discovery, Integration, and Therapeutic Potential

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Cell Metabolism".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 555

Special Issue Editor


E-Mail Website
Guest Editor
Ginger Judge Science Center, Biology & Biotechnology Department, School of Science and Technology, Endicott College, Beverly, MA, USA
Interests: Parkinson’s disease; senolytics and senescence; glia; early diagnosis strategies; bioinformatics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomarkers are essential tools in the fight against neurodegenerative diseases. They play a pivotal role in establishing an early diagnosis, prognosis, in treatment monitoring, and the identification of therapeutic targets. Advancements in biomarker research refine our ability to diagnose and treat neurodegenerative conditions and enhance our understanding of the complex biological processes underlying these diseases.

Biomarker categories are quite diverse. They can include genetic markers, proteomic signatures, imaging, and cellular characteristics. However, metabolites are particularly attractive for their relative ease of clinical access and analysis. Furthermore, when integrated with multi-omics data, metabolic biomarkers offer unique insights into disease mechanisms and therapeutic possibilities. Additionally, machine learning and other computational approaches are transforming how we analyze and interpret these rich datasets, leading to the discovery of novel biomarkers and improving our ability to translate findings into clinical practice.

This Special Issue welcomes submissions exploring all facets of metabolomic biomarker research in neurodegenerative diseases. We encourage a broad range of contributions, including but not limited to the following:

  • Discovery of novel metabolite biomarkers of neurodegeneration.
  • New insights into established metabolic biomarkers of neurodegeneration.
  • Methodological advances in metabolomic data collection, integration, and analysis.
  • Applications of machine learning and/or bioinformatics in metabolomic biomarker discovery.
  • Translational studies leveraging metabolomic biomarkers for therapeutic development or precision medicine.
  • Cross-disciplinary approaches integrating metabolomics with other omics data to address critical challenges in neurodegeneration research.

By welcoming a wide variety of studies, we aim to capture the diversity and innovation in this important and dynamic field.

Dr. Robert Logan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • neurodegeneration
  • metabolites
  • metabolic pathways
  • metabolomic
  • Alzheimer’s disease
  • Parkinson’s disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

23 pages, 1113 KiB  
Systematic Review
Salivaomics: New Frontiers in Studying the Relationship Between Periodontal Disease and Alzheimer’s Disease
by Giuseppina Malcangi, Grazia Marinelli, Alessio Danilo Inchingolo, Irma Trilli, Laura Ferrante, Lucia Casamassima, Paola Nardelli, Francesco Inchingolo, Andrea Palermo, Angelo Michele Inchingolo and Gianna Dipalma
Metabolites 2025, 15(6), 389; https://doi.org/10.3390/metabo15060389 - 10 Jun 2025
Viewed by 342
Abstract
Background: This study explores the link between oral biofluids, microbial dysbiosis, and Alzheimer’s disease (AD), highlighting saliva and gingival crevicular fluid (GCF) as non-invasive diagnostic sources. AD onset and progression appear to be influenced not only by genetic and environmental factors but also [...] Read more.
Background: This study explores the link between oral biofluids, microbial dysbiosis, and Alzheimer’s disease (AD), highlighting saliva and gingival crevicular fluid (GCF) as non-invasive diagnostic sources. AD onset and progression appear to be influenced not only by genetic and environmental factors but also by changes in the oral microbiome and related inflammatory and metabolic alterations. As global populations age, the incidence of AD is projected to rise significantly. Emerging evidence implicates the oral microbiome and salivary metabolites in neurodegenerative pathways, suggesting that oral health may mirror or influence brain pathology. Materials and Methods: A systematic review of recent multi-omics studies was performed, focusing on salivary and GCF analysis in patients with AD, those with mild cognitive impairment (MCI), and cognitively healthy individuals. Databases searched included PubMed, Web of Science, and Scopus, following PRISMA guidelines. Results: Across the 11 included studies, significant alterations were reported in both the salivary microbiome and metabolome in AD patients. Notable microbial shifts involved increased abundance of Veillonella parvula and Porphyromonas gingivalis, while key metabolites such as L-tyrosine, galactinol, and mannitol were consistently dysregulated. These biomarkers correlated with cognitive performance and systemic inflammation. Conclusions: Oral biofluids represent promising, accessible sources of biomarkers for early AD detection. Multi-omics integration reveals the oral–brain axis as a potential target for diagnosis, monitoring, and therapeutic strategies. Full article
Show Figures

Figure 1

Back to TopTop